Results 111 to 120 of about 694 (158)

Oral Availability of Bilastine

Clinical Drug Investigation, 2013
Bilastine (Bilaxten™) is a novel non-sedating H1 receptor antagonist (antihistamine) developed in the dosage form of oral tablets and indicated for the treatment of allergic rhinitis (seasonal and perennial) and urticaria. Several clinical trials have been performed in order to determine the efficacy and safety of bilastine.
B, Sádaba, A, Gómez-Guiu, J R, Azanza, I, Ortega, R, Valiente   +4 more
openaire   +4 more sources

Bilastine: an environmental risk assessment

Drug and Chemical Toxicology, 2015
Bilastine is a new oral selective, non-sedating histamine H1 antagonist for the symptomatic treatment of allergic rhinoconjunctivitis and urticaria. The European Medicines Agency requires an Environmental Risk Assessment (ERA) for all novel medicines for human use.To calculate the bilastine predicted environmental concentration in surface water (PECsw;
María Luisa, Lucero, Armin, Peither, Francisco, Ledo   +2 more
openaire   +2 more sources

Bilastine for the relief of allergy symptoms

Drugs of Today, 2011
Bilastine is a potent inhibitor of the histamine H1 receptor. It was recently approved in 28 countries of the European Union for the symptomatic treatment of allergic rhinoconjunctivitis and urticaria in adults and children older than 12 years. Data from preclinical studies confirmed its selectivity for the histamine H1 receptor over other receptors ...
B, Sádaba Díaz de Rada, J R, Azanza Perea, A, Gomez-Guiu Hormigos   +2 more
openaire   +2 more sources

Bilastine in allergic rhinoconjunctivitis and urticaria

Allergy: European Journal of Allergy and Clinical Immunology, 2010
To cite this article: Bachert C, Kuna P, Zuberbier T. Bilastine in allergic rhinoconjunctivitis and urticaria. Allergy 2010; 65 (Suppl. 93): 1–13.AbstractAllergic rhinoconjunctivitis and urticaria are increasing in prevalence in many developed countries.
Torsten Zuberbier, Piotr Kuna, Claus Bachert   +2 more
exaly   +2 more sources

Bilastine

Drugs, 2012
Bilastine is an orally administered, second-generation antihistamine used in the symptomatic treatment of seasonal or perennial allergic rhinoconjunctivitis and urticaria. In two well designed phase III trials, 14 days' treatment with bilastine was associated with a significantly lower area under the effect curve (AUEC) for the reflective total symptom
openaire   +2 more sources

Role of Bilastine in Allergic Rhinitis: A Narrative Review

Journal of the Association of Physicians of India, 2023
Allergic rhinitis (AR) is considered a trivial disease and is often self-treated with over-the-counter drugs and home remedies. However, AR is a contributing risk factor for asthma associated with complications, including chronic cough, eosinophilic esophagitis, and otitis media with effusion.
Mangesh, Tiwaskar, Agam, Vora, Kamlesh, Tewary, Anupam, Prakash, K K, Tripathi, Subir, Jain, , Ilambarati, Gayatri, Pandit, B P, Singh   +8 more
openaire   +2 more sources

Bilastine as a Potential Treatment in Allergic Rhinitis

American Journal of Rhinology & Allergy, 2014
Background Allergic rhinitis is a very frequent disease. H 1 antihistamines have been used for treatment of allergic rhinitis for more than 5 decades.
Krzysztof Kowal, Dubuske, Lawrence
openaire   +2 more sources

Alternative Synthesis of Bilastine

Synthetic Communications, 2011
Abstract A new and efficient synthesis of the non-sedating histamine H1 receptor antagonist Bilastine is reported. The new route employs a convergent strategy, with a longest linear sequence of five steps, giving slightly improved yields over the previous routes.
Steven J. Collier, Xiang Wu, Zhiying Poh, Gurubatham Abraham Rajkumar, Larry Yet   +4 more
openaire   +1 more source

Preclinical toxicity profile of oral bilastine

Drug and Chemical Toxicology, 2012
As part of the bilastine development program, and as mandated by regulatory authorities, several studies were performed with oral bilastine in different animal species to evaluate its toxicity profile. Toxicokinetic analyses conducted in tandem to evaluate systemic exposure, gender differences, and dose proportionality in the different animal species ...
María Luisa, Lucero, Joseba K, Arteche, E W, Sommer, Agustín, Casadesus   +3 more
openaire   +2 more sources

An overview of bilastine metabolism during preclinical investigations

Drug and Chemical Toxicology, 2012
Knowledge of the biotransformation of oral H₁ antihistamines is clinically important because it can define their pharmacokinetic profile through possible effects on absorption (i.e., first-pass metabolism) and elimination. Further, clinically significant interactions with inhibitors of cytochrome P450 (CYP) have previously been reported for drugs of ...
María Luisa, Lucero, Ana, Gonzalo, Rory, Mumford, Mónica, Betanzos, Ana, Alejandro   +4 more
openaire   +2 more sources